Affordable Access

Successful use of anti-CD20 (rituximab) in severe, life-threatening childhood immune thrombocytopenic purpura.

Authors
  • Bengtson, Kristi L
  • Skinner, Michael A
  • Ware, Russell E
Type
Published Article
Journal
The Journal of Pediatrics
Publisher
Elsevier
Publication Date
Nov 01, 2003
Volume
143
Issue
5
Pages
670–673
Identifiers
PMID: 14615744
Source
Medline
License
Unknown

Abstract

Thrombocytopenia with life-threatening hemorrhage in childhood immune thrombocytopenic purpura is rare, but effective therapeutic options are limited for the patient with bleeding. We report the efficacy of humanized anti-CD20 monoclonal antibody (rituximab, Rituxan) therapy for an infant with severe, refractory life-threatening immune thrombocytopenic purpura.

Report this publication

Statistics

Seen <100 times